Advertisement
The conference call will be accessible via Telik's website athttp://www.telik.com or by telephone at 800-398-9367 or 612-332-7517. Anarchive of the conference call will be available on the Telik website or bytelephone at 800-475-6701 or 320-365-3844, access code 966597. The archivewill be available from approximately 6:00 p.m. Eastern time on November 5through November 19, 2008.
Advertisement
Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused ondiscovering, developing and commercializing novel small molecule drugs totreat serious diseases. The company's most advanced investigational drugcandidates in clinical development are TELINTRA(R), a modified glutathioneanalog for the treatment of cytopenias due to myelodysplastic syndrome orchemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment ofadvanced ovarian cancer and non-small cell lung cancer. Telik's productcandidates were discovered using its proprietary drug discovery technology,TRAP(R), which enables the rapid and efficient discovery of small moleculedrug candidates.
TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks orregistered trademarks of Telik, Inc.
SOURCE Telik, Inc.
